Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine.
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Axel
A
Grothey
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Daniel J
DJ
Sargent
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068818:Cetuximab / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D005472:Fluorouracil / Q000008:administration & dosage; D020558:GTP Phosphohydrolases / Q000235:genetics; D005838:Genotype; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics; D053842:Microsatellite Instability; D009367:Neoplasm Staging; D000077594:Nivolumab; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D000077544:Panitumumab; D010641:Phenotype; D057285:Precision Medicine; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C117307:KRAS protein, human; D008565:Membrane Proteins; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077594:Nivolumab; D000077544:Panitumumab; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020558:GTP Phosphohydrolases; C579846:NRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras); D000068818:Cetuximab; D005472:Fluorouracil